Phase 1/2a, Double-blind, Placebo-controlled, Single and Multiple Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ARO-DIMERPA in Adult Subjects With Mixed Hyperlipidemia
Latest Information Update: 10 Feb 2026
At a glance
- Drugs ARO DIMER PA (Primary)
- Indications Hyperlipidaemia
- Focus Adverse reactions
- Sponsors Arrowhead Pharmaceuticals
Most Recent Events
- 27 Jan 2026 According to Arrowhead Pharmaceuticals media release, the first patient have been dosed in this trial.
- 09 Jan 2026 Planned primary completion date changed from 1 Jul 2027 to 1 Jun 2026.
- 09 Jan 2026 Status changed from not yet recruiting to recruiting.